Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy
We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain. He was subsequently started on rivaroxaban therapy for a combined treatment period of 12 months, during and after wh...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2017/3628127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561805730250752 |
|---|---|
| author | Jonathan M. Yaghoubian Jacob Adashek Bahareh Yaghoubian-Yazi Menachem Nagar Nojan Toomari Richard J. Pietras Uri M. Ben-Zur |
| author_facet | Jonathan M. Yaghoubian Jacob Adashek Bahareh Yaghoubian-Yazi Menachem Nagar Nojan Toomari Richard J. Pietras Uri M. Ben-Zur |
| author_sort | Jonathan M. Yaghoubian |
| collection | DOAJ |
| description | We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain. He was subsequently started on rivaroxaban therapy for a combined treatment period of 12 months, during and after which he persisted to have evidence of a DVT. The patient’s prescribed drug regimen was changed from rivaroxaban to warfarin, which demonstrated a rapid resolution of the DVTs as determined by ultrasound assessment of our patient’s lower extremity veins. Rivaroxaban, a factor Xa inhibitor, is a well-known oral anticoagulant that is used for a variety of indications and has become a mainstay in the treatment of deep vein thrombosis. With the introduction and emergence of this medication in the clinic, postmarketing reports of efficacy or lack thereof are important to review. In conclusion, we anticipate that it is likely that there are other patients with DVTs who may not respond to rivaroxaban and for whom alternative anticoagulation therapies should be explored. |
| format | Article |
| id | doaj-art-dec4acef024f449cb25aa7f4bbd6b4ce |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-dec4acef024f449cb25aa7f4bbd6b4ce2025-02-03T01:24:15ZengWileyCase Reports in Cardiology2090-64042090-64122017-01-01201710.1155/2017/36281273628127Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban TherapyJonathan M. Yaghoubian0Jacob Adashek1Bahareh Yaghoubian-Yazi2Menachem Nagar3Nojan Toomari4Richard J. Pietras5Uri M. Ben-Zur6College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USACollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USAThe Cardiovascular Institute of Greater Los Angeles, Tarzana, CA, USAFaculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelProvidence Tarzana Medical Center, Tarzana, CA, USADivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USACollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USAWe present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain. He was subsequently started on rivaroxaban therapy for a combined treatment period of 12 months, during and after which he persisted to have evidence of a DVT. The patient’s prescribed drug regimen was changed from rivaroxaban to warfarin, which demonstrated a rapid resolution of the DVTs as determined by ultrasound assessment of our patient’s lower extremity veins. Rivaroxaban, a factor Xa inhibitor, is a well-known oral anticoagulant that is used for a variety of indications and has become a mainstay in the treatment of deep vein thrombosis. With the introduction and emergence of this medication in the clinic, postmarketing reports of efficacy or lack thereof are important to review. In conclusion, we anticipate that it is likely that there are other patients with DVTs who may not respond to rivaroxaban and for whom alternative anticoagulation therapies should be explored.http://dx.doi.org/10.1155/2017/3628127 |
| spellingShingle | Jonathan M. Yaghoubian Jacob Adashek Bahareh Yaghoubian-Yazi Menachem Nagar Nojan Toomari Richard J. Pietras Uri M. Ben-Zur Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy Case Reports in Cardiology |
| title | Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy |
| title_full | Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy |
| title_fullStr | Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy |
| title_full_unstemmed | Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy |
| title_short | Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy |
| title_sort | incomplete resolution of deep vein thromboses during rivaroxaban therapy |
| url | http://dx.doi.org/10.1155/2017/3628127 |
| work_keys_str_mv | AT jonathanmyaghoubian incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT jacobadashek incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT baharehyaghoubianyazi incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT menachemnagar incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT nojantoomari incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT richardjpietras incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy AT urimbenzur incompleteresolutionofdeepveinthrombosesduringrivaroxabantherapy |